APT Medical Inc. (SHA:688617)
China · Delayed Price · Currency is CNY 248.25
+8.22 (3.42%)
Sep 30, 2026, 3:00 PM CST
APT Medical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 34,563 | 34,308 | 36,094 | 25,854 | 20,463 | 18,668 | |
Market Cap Growth | -21.80% | -4.95% | 39.61% | 26.35% | 9.62% | - |
Enterprise Value | 33,185 | 33,003 | 35,194 | 24,788 | 19,457 | 17,519 |
Last Close Price | 248.25 | 242.26 | 254.60 | 182.44 | 143.51 | 130.20 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 37.58 | 41.81 | 53.62 | 48.42 | 57.16 | 89.78 |
Forward PE | 34.65 | 33.30 | 41.69 | 41.48 | 50.33 | 65.88 |
PS Ratio | 11.93 | 13.28 | 17.47 | 15.67 | 16.83 | 22.53 |
PB Ratio | 11.08 | 10.96 | 14.13 | 13.18 | 11.43 | 10.42 |
P/TBV Ratio | 13.01 | 12.95 | 17.47 | 14.56 | 11.87 | 10.69 |
P/FCF Ratio | 40.42 | 50.29 | 387.51 | 53.09 | 91.25 | 1332.38 |
P/OCF Ratio | 32.23 | 35.45 | 48.55 | 37.52 | 55.69 | 102.92 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 11.46 | 12.77 | 17.04 | 15.02 | 16.00 | 21.14 |
EV/EBITDA Ratio | 29.47 | 33.39 | 44.49 | 42.67 | 47.96 | 86.10 |
EV/EBIT Ratio | 32.90 | 37.17 | 49.32 | 47.23 | 53.31 | 99.72 |
EV/FCF Ratio | 38.81 | 48.38 | 377.84 | 50.90 | 86.76 | 1250.43 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.01 | 0.00 | 0.05 | 0.03 | 0.03 |
Debt / EBITDA Ratio | 0.01 | 0.02 | 0.01 | 0.15 | 0.13 | 0.22 |
Debt / FCF Ratio | 0.02 | 0.03 | 0.12 | 0.19 | 0.24 | 3.32 |
Net Debt / Equity Ratio | -0.45 | -0.48 | -0.42 | -0.63 | -0.60 | -0.66 |
Net Debt / EBITDA Ratio | -1.26 | -1.51 | -1.35 | -2.15 | -2.66 | -5.78 |
Net Debt / FCF Ratio | -1.65 | -2.19 | -11.48 | -2.56 | -4.81 | -83.99 |
Asset Turnover | 0.85 | 0.78 | 0.74 | 0.69 | 0.57 | 0.64 |
Inventory Turnover | 1.72 | 1.59 | 1.60 | 1.46 | 1.18 | 1.27 |
Quick Ratio | 3.45 | 3.50 | 2.92 | 2.36 | 2.90 | 6.53 |
Current Ratio | 4.67 | 4.62 | 3.98 | 2.99 | 3.78 | 7.98 |
Return on Equity (ROE) | 30.82% | 28.42% | 29.14% | 27.82% | 18.99% | 17.39% |
Return on Assets (ROA) | 18.43% | 16.74% | 16.06% | 13.67% | 10.76% | 8.44% |
Return on Invested Capital (ROIC) | 50.70% | 49.11% | 57.22% | 64.41% | 47.40% | 31.43% |
Return on Capital Employed (ROCE) | 31.70% | 27.80% | 27.70% | 26.40% | 20.10% | 9.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.70% | 2.39% | 1.86% | 2.07% | 1.75% | 1.11% |
FCF Yield | 2.47% | 1.99% | 0.26% | 1.88% | 1.10% | 0.07% |
Dividend Yield | 0.40% | 0.41% | 0.47% | 0.52% | 0.55% | 0.36% |
Payout Ratio | 14.92% | 20.75% | 19.90% | 21.02% | 19.28% | 15.96% |
Buyback Yield / Dilution | 0.26% | -0.05% | 0.27% | 0.16% | -2.99% | -31.45% |
Total Shareholder Return | 0.66% | 0.36% | 0.74% | 0.69% | -2.44% | -31.09% |